The group performed FDG-PET/CT and CT perfusion imaging scans in a phase I clinical trial of the use of bevacizumab plus ipilimumab to treat patients with unresectable stage III or IV melanoma. The researchers found that patients with FDG-PET/CT images showing partial metabolic response achieved longer disease-free survival than those with stable metabolic disease or progressive metabolic disease.
Bevacizumab, marketed by Genentech as Avastin, has received clearance from the U.S. Food and Drug Administration (FDA) to inhibit angiogenesis, or the development of new blood vessels that advance the progress of a tumor. Ipilimumab is marketed under the brand name Yervoy by Bristol-Myers Squibb and was cleared by the FDA in March 2011 to treat patients with advanced melanoma.
In the Dana-Farber study, helical CT, contrast-enhanced CT, and FDG-PET/CT were performed on 21 patients at baseline. Helical CT and contrast-enhanced CT scans were repeated at 12 weeks and 24 weeks, while FDG-PET/CT imaging was performed at eight and 16 weeks after treatment with the drug combination, according to Dr. Pamela DiPiro, co-author and clinical director of CT at Dana-Farber. She presented the results at the recent 2011 RSNA meeting in Chicago.
The researchers measured anatomic response on the helical CT scans using the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Maximum standardized uptake values were used to evaluate metabolic response on FDG-PET based on the European Organization for Research and Treatment of Cancer (EORTC) guidelines. In addition, a kinetic analysis was performed on contrast-enhanced CT images to estimate tumor blood flow, mean transit time, and volume of distribution.
At eight weeks, six patients had a metabolic partial response to treatment, seven patients had stable disease, and eight patients had progressive disease.
Of the patients who had FDG-PET/CT scans at 16 weeks, six had a metabolic partial response to therapy, four had stable disease, and four had progressive disease. Among the evaluable perfusion CT studies, the researchers detected reductions in perfusion parameters in patients with metabolic partial response to therapy, while there were increases in patients with metabolic progressive disease.
The most significant finding was that FDG-PET/CT images of patients who had a metabolic partial response indicated that these individuals achieved a longer disease-free survival than those with stable or progressive metabolic disease, DiPiro said.
However, there were not enough dynamic contrast-enhanced CT data to reach statistic significance regarding disease-free survival, she added.
"While the results are preliminary and further studies are needed, these results suggest both dynamic contrast-enhanced CT and FDG-PET may be important imaging biomarkers of efficacy for these therapeutic targets in this clinical setting," DiPiro told AuntMinnie.com. "If successful, this could provide an early means of determining treatment efficacy for melanoma patients or, conversely, identify when treatments are not working and discontinuation and/or alternative therapy is warranted."
She did note that bevacizumab and ipilimumab were not evaluated separately to determine the efficacy of each drug for melanoma. In the study, patients received ipilimumab immediately followed by bevacizumab.
"There was no time to look at one [drug] or the other to see if there were any confounding effects," DiPiro said. "If future studies use a mono phase [to study the drugs independently], that could be helpful."
Still, the findings regarding FDG-PET's and contrast-enhanced CT's capabilities could help evaluate early response to novel therapeutics, particularly in lesions increasing in size due to inflammation and in tumor destruction, where standard response criteria do not predict response.If you like this content, please share it with a colleague!
Copyright © 2012 AuntMinnie.com